Conventional and combined insulin treatment in type 2 diabetes;Konventionelle und kombinierte insulintherapie bei typ-2-diabetes

Diabetologe

Volumn 2, Issue 4, 2006, Pages 304-313

  Janka, H U ^a  

^a Klinikum Bremen Nord   (Germany)

Author keywords

BOT; Conventional insulin therapy; Glargine; Prandial insulin; Weight gain

Indexed keywords

EID: 33748937589     PISSN: 18609716     EISSN: 18609724     Source Type: Journal    
DOI: 10.1007/s11428-006-0064-4     Document Type: Article

References (46)

1. American Diabetes Association (2006) Standards of medical care in diabetes - 2006, Diabetes Care [Suppl 1] 29: S4-S42
2. Bachmann W (1982) Insulin plussulfonylurea - a(n) (im)possible combination? Dtsch Med Wochenschr 107: 163-165
3. Bastyr EJ III, Johnson ME,Trautmann ME et al. (1999) Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure. Clin Ther 21: 1703-1714
4. Basu R, Schwenk WE, Rizza RA (2004) Both fasting glucose production and disappearance are abnormal in peoplewith "mild" and "severe" type 2 diabetes. Am J Physiol Endocrinol Metab 287: E55-E62
5. Batty GD, Shipley MJ, Jarrett RJ et al. (2005) Obesity and overweight in relation to organ-specific cancer mortality in London (UK): findings from the original Whitehall study. Intern J Obesity 29: 1267-1274
6. Bierwirth RA, Kron P, Lippmann-Grob B et al. (2003) Die TEMPO-Studie: Kostenanalyse in der diabetologischen Schwerpunktpraxis und Definition diabetesspezifischer Risikoprofile. Diabetes Stoffwechsel 12: 83-94
7. Bowker SL,Veugelers P, Majumdar SR et al. (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29: 254-258
8. DeFronzo RA, Ferrannini E, Simonson DC (1989) Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 38: 387-395
9. Dormandy JA, Charbonell B, Eckland DJA et al. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study ("prospective pioglitazone clinical trial in macrovascular events"): a randomised controlled trial. Lancet 366: 1279-1289
10. European Diabetes Policy Group (1999) A desktop guide to type 2 diabetes mellitus. Diabet Med 16: 716-730
11. Ferrannini E, Gastaldelli A, Miyazaki Y et al. (2005) β-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 90: 493-500
12. Fisher SJ, Kahn CR (2003) Insulin signaling is required for insulin's direct and indirect action on hepatic glucose production. J Clin Invest 111: 463-468
13. Goudswaard AN, Furlong NJ, Valk GD et al. (2004) Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 4: CD003418, DOI:10.1002/14651858.CD003418.pub2
14. Haring HU, Joost HG, Laube H et al. (2003) Anti-hyperglykämische Therapie des Diabetes mellitus Typ 2. Evidenzbasierte Diabetes-Leitlinie DDG. Diabetes Stoffwechsel [Suppl 2] 12: 13-31
15. Hauner H, Köster I, Ferber L von (2003) Prävalenz des Diabetes mellitus in Deutschland 1998-2001: Sekundärdatenanalyse einer Versichertenstichprobe der AOK Hessen/KV Hessen. Dtsch Med Wochenschr 128: 2632-2638
16. Henry RR, Gumbiner B, Ditzler T et al. (1993) Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial. Diabetes Care 16: 21-31
17. Hirsch IB (2005) Insulin analogues. N Engl J Med 352: 174-183
18. Holstein A, Egberts EH (2006) Traditionelle Metformin-Kontraindikationen - mehr Schaden als Nutzen? Dtsch Med Wochenschr 131: 105-110
19. Janka HU, Plewe G, Riddle MC et al. (2005) Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 28: 254-259
20. Janka HU, Plewe G, Busch K (in press) Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes. Am J Geriatr in press
21. Koivisto VA, Juominen JA, Ebeling P (1999) Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. Diabetes Care 22: 459-462
22. Krssak M, Brehm A, Bernroider E et al. (2004) Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. Diabetes 53: 3048-3056
23. Landstedt-Hallin L, Adamson U, Arner P et al. (1995) Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. Diabetes Care 18: 1183-1186
24. Liebl A, Neiss A, Spannheimer A et al. (2002) Complications, co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany - results from the CODE-2 study. Exp Clin Endocrinol Diabetes 110: 10-16
25. Lundershausen R, Potthoff F, Kaiset M et al. (2006) Supplementäre Insulintherapie bei Patienten mit Typ-2-Diabetes - die Phazit-Studie. Diabetologie 1: 54-59
26. Müller UA, Femerling M, Risse A (2002) Metabolic control with conventional (CIT) or supplementary (SIT) insulin therapy after intervention by a structural treatment and teaching programme in patients with diabetes mellitus type 2 in member hospitals of the ASD. Diabetologia [Suppl 2] 45: A256
27. Nordrheinische Gemeinsame Einrichtung Disease-Management-Programme GbR (2004) Qualitätssicherungsbericht 2004: Disease-Management-Programme in Nordrhein. Lilodruck Möhker & Sievering, Dusseldorf, http://www.kvno.de/
28. Petersen KF, Dufour S, Befroy D et al. (2005) Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54: 603-608
29. Polonsky WH, Fisher L, Guzman S et al. (2005) Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care28: 2543-2545
30. Raskin P, Allen E, Hollander P et al. (2005) Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 28: 260-265
31. Ridderstråle M, Gudbjörnsdottir S, Eliasson B et al. (2006) Obesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish National Diabetes Register. J Intern Med 259: 314-322
32. Riddle MC, Rosenstock J, Gerich J (2003) The treatto-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26: 3080-3086
33. Rosenstock J, Dailey G, Massi-Benedetti M et al. (2005) Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 28: 950-955
34. Rosenstock J, Sugirnoto D, Strange P et al. (2006) Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 29: 554-559
35. Ryysy L, Hakkinen A, Goto T et al. (2000) Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49: 749-758
36. Schiel R, Müller UA (1999) Intensive or conventional therapy in type 2 diabetic patients? A population based study on metabolic control and quality of life (The JEVIN-trial). Exp Clin Endocrinol Diab 107: 505-511
37. Siebenhofer A, Plank J, Berghold A et al. (2004) Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 4: CD003287, DOI:10.1002/14651858.CD003287.pub3
38. Stolzenberg-Solomon RZ, Graubard BI, Chari S et al. (2005) Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA 294: 2872-2878
39. Taskinen MR, Sane T, Helve E et al. (1989) Bedtime insulin for suppression of overnight free-fatty acid, blood glucose, and glucose production in NIDDM. Diabetes 38: 580-588
40. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators (1996) Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 335: 217-225
41. Tschritter O, Fritsche A, Gallwitz B et al. (2005) Langwirkende Insulinanolga in der Therapie des Diabetes mellitus Typ 1 und Typ 2: Eine Zusammenfassung der klinischen Studien und Metaanalysen. Diabetes Stoffwechsel 14: 375-382
42. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853
43. Wright A, Burden ACF, Paisey RB et al. (2002) Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 25: 330-333
44. Wulffeié MG, Kooy A, Lehert P et al. (2002) Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes 25: 2133-2140
45. Yang YX, Hennessy S, Lewis JD (2004) Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 127: 1044-1050
46. Yki-Järvinen H, Kauppinen-Mäkelin R, Jiikkainen M et al. (2006) Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 49: 442-451